Bharat Biotech’s 'Covaxin' gets SEC nod for phase 2-3 clinical trials on 2 to 18 year-olds


Subject Expert Committee (SEC) gave nod to Bharat Biotech’s ‘Covaxin’ for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the ‘Covaxin’ is being used in adults. ‘Covaxin’ is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.



READ SOURCE

READ  Tata Motors sees EV sales doubling in FY-21, to cross 1000 mark in FY-20

LEAVE A REPLY

Please enter your comment!
Please enter your name here